mRNA-1365 (Profile 2)
BiologicalSterile liquid for injection
NCT Number: NCT07764237
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups
Interested in participating?
Request Info60 year and older
All sexes
Interventional
Phase 1
Diex Recherche Quebec, Québec, Quebec, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Time frame: Up to Day 7 (the day of study intervention and 6 subsequent days)
Time frame: Up to Day 28 (the day of study intervention and 27 subsequent days)
Time frame: Up to End of Study (EOS) (Day 181)
Time frame: Day 29
Time frame: Day 29
Time frame: Day 29
Contact information is provided by the study sponsor or research team.
ModernaTX, Inc.
Industry
A Phase 1, Randomized, Open-label Staggered Dose-escalation and Observer-blind Expansion Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Multicomponent Vaccine mRNA-1365 (Profile 2 [RSV and hMPV]) in Healthy Adults ≥60 Years of Age
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07653100
Respiratory Syncytial Virus (RSV)
Visakhapatnam, Andhra Pradesh, India
View Trial DetailsNCT07482657
Infections, Mononegavirales Infections
Bangkok, Thailand
View Trial DetailsNCT06851806
Respiratory Syncytial Virus (RSV)
Hyderabad, India
View Trial DetailsNCT07543380
Respiratory Syncytial Virus (RSV)
Tsuchiura, Ibaraki, Japan
View Trial Details